News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Kite Pharma, Inc. To Highlight Cancer Immunotherapy T Cell Manufacturing Process At 2014 American Society of Clinical Oncology Annual Meeting

5/30/2014 7:07:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SANTA MONICA, Calif., May 30, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the Company will provide details on key features of the rapid, 6-day manufacturing process that is expected to underlie its most advanced personalized cancer immunotherapy program. The technology is expected to underpin a Kite clinical trial in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL), a highly refractory and aggressive blood cancer, which Kite expects to commence in early 2015. Elements of Kite's manufacturing process will be featured in a poster presentation during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, May 30 to June 3, 2014.

ASCO 2014 Poster Presentation
Title: Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.

Authors: Marc Better1, Omar Pugach1, Lily Lu2, Robert Somerville2, Sadik Kassim2, James Kochenderfer2, Steven A. Rosenberg2, Margaret A. Marshall1, Adrian Bot1, Keith B. Nolop1, Margo Roberts1, Steven Feldman2. Key: 1 Kite Pharma, 2 National Cancer Institute

Abstract: #3079

Poster: #146

General Poster Session: Developmental Therapeutics - Immunotherapy

Date and Location: Sunday, June 1, 2014, 8:00am 11:45am Central Time; S Hall A2

About Kite Pharma
Kite Pharma, Inc., is a privately held clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments. Kite is based in Santa Monica, CA.

Kite Contact:
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer

For Media:Justin Jackson
For Investor Inquiries: Kimberly Minarovich
Burns McClellan
(212) 213-0006

SOURCE Kite Pharma, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus